HXP124

Hexima’s lead product, HXP124, is a topical antifungal treatment for onychomycosis or fungal nail infections.

Now Recruiting

Hexima is recruiting volunteers for clinical trials of HXP124. Click below to find out more and to register your interest.

R&D Webinar: 25 March 2021

Latest NailMail Newsletter

Thank you to those that joined us for our first R&D Webinar. We had a great response and an engaged audience who we hope found value in our presentation. A recording of the webinar is now available.

NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.

R&D Webinar: 25 March 2021

Thank you to those that joined us for our first R&D Webinar. We had a great response and an engaged audience who we hope found value in our presentation. A recording of the webinar is now available.

Latest NailMail Newsletter

NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo